- Home
- YORW vs ALMS Comparison
YORW vs ALMS Comparison
Compare YORW & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YORW
- ALMS
- Stock Information
- Founded
- YORW 1816
- ALMS 2021
- Country
- YORW United States
- ALMS United States
- Employees
- YORW N/A
- ALMS N/A
- Industry
- YORW Water Supply
- ALMS
- Sector
- YORW Utilities
- ALMS
- Exchange
- YORW Nasdaq
- ALMS NYSE
- Market Cap
- YORW 498.1M
- ALMS 469.0M
- IPO Year
- YORW N/A
- ALMS 2024
- Fundamental
- Price
- YORW $33.43
- ALMS $8.82
- Analyst Decision
- YORW
- ALMS Strong Buy
- Analyst Count
- YORW 0
- ALMS 6
- Target Price
- YORW N/A
- ALMS $29.60
- AVG Volume (30 Days)
- YORW 74.5K
- ALMS 148.8K
- Earning Date
- YORW 11-07-2024
- ALMS 02-15-2025
- Dividend Yield
- YORW 2.62%
- ALMS N/A
- EPS Growth
- YORW N/A
- ALMS N/A
- EPS
- YORW 1.48
- ALMS N/A
- Revenue
- YORW $74,189,000.00
- ALMS N/A
- Revenue This Year
- YORW $7.70
- ALMS N/A
- Revenue Next Year
- YORW $5.33
- ALMS N/A
- P/E Ratio
- YORW $22.61
- ALMS N/A
- Revenue Growth
- YORW 9.03
- ALMS N/A
- 52 Week Low
- YORW $33.22
- ALMS $7.66
- 52 Week High
- YORW $41.96
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- YORW 29.36
- ALMS N/A
- Support Level
- YORW $34.59
- ALMS N/A
- Resistance Level
- YORW $35.35
- ALMS N/A
- Average True Range (ATR)
- YORW 0.65
- ALMS 0.00
- MACD
- YORW -0.13
- ALMS 0.00
- Stochastic Oscillator
- YORW 8.64
- ALMS 0.00
About YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and two wastewater treatment systems. The company operates within its franchised territory, which covers more than 54 municipalities within York County, Pennsylvania.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.